Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA

Medicine & Life Sciences

• Linagliptin 100%
• Type 2 Diabetes Mellitus 46%
• Heart Failure 45%
• Hospitalization 36%
• Kidney 33%
• Kidney Diseases 32%
• Stroke Volume 22%
• Cardiovascular Diseases 17%
• Dipeptidyl-Peptidase IV Inhibitors 16%
• Placebos 12%
• Glomerular Filtration Rate 11%
• Statistical Models 6%
• Random Allocation 6%
• Standard of Care 6%
• Proportional Hazards Models 5%
• Albumins 5%
• Hemoglobins 4%
• Creatinine 4%
• Diabetes Mellitus 4%
• Urine 4%
• Health Care Outcome Assessment 4%
• Incidence 3%